ArticleFrontiers in pediatrics2025
Novel technique of sclerotherapy for superficial lymphatic malformation.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Study on the Application of Indocyanine Green Lymphography in the Management of Microcystic Lymphatic Malformation: A Randomized Clinical Trial.Children (Basel, Switzerland) · 2026Article
- Thigh lymphocutaneous fistula in a child.Journal of vascular surgery. Venous and lymphatic disorders · 2026Article
- Case report: Long-term local control of recurrent lymphatic malformations using minocycline sclerotherapy following surgical resection in a dog.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Superficial lymphatic malformation (SLM), previously known as lymphangioma circumscriptum, is characterized by skin lesions that sometimes require interventional treatment. However, an effective treatment has yet to be established. We proposed an effective sclerotherapy procedure based on the pathophysiology of SLM. Methods: Seven patients with SLM who were treated at our hospital between April 2015 and April 2024 were retrospectively enrolled. To maximize the treatment effects, sclerotherapy with bleomycin targeting the SLM and LM deep beneath the SLM was performed. Results: Of the seven patients, four were females, and three were males. The SLM sites were mucosal lesions in four cases and skin lesions in three cases. The median age at the first sclerotherapy was 10 (1-18) years. A median of one course (1-3) of sclerotherapy resulted in a marked reduction of SLM lesions on gross evaluation to the satisfaction of the patient. The median observation period was 451 (59-2,901) days. No serious complications occurred, except for transient vomiting in one patient and temporary skin pigmentation in two patients. No patient experienced recurrence requiring retreatment. Conclusion: Our study suggests that sclerotherapy for the SLM and LM deep beneath the SLM may be an effective treatment for SLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.